Tomocube Inc
Tomocube, Inc. engages in the manufacture and sale of optical devices and medical equipment. Its holotomography (HT) products include HT-X1 for live-cell imaging and analysis; and HT-2H for 3D live cell imaging. The company also offers TomoAnalysis, a 3D image visualization and analysis software. In addition, it provides accessories, such as HT-ready 96 well plates; TomoDish that is designed to a… Read more
Tomocube Inc (475960) - Net Assets
Latest net assets as of September 2025: ₩37.60 Billion KRW
Based on the latest financial reports, Tomocube Inc (475960) has net assets worth ₩37.60 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩41.04 Billion) and total liabilities (₩3.43 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩37.60 Billion |
| % of Total Assets | 91.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Tomocube Inc - Net Assets Trend (2021–2024)
This chart illustrates how Tomocube Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tomocube Inc (2021–2024)
The table below shows the annual net assets of Tomocube Inc from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩41.99 Billion | +137.13% |
| 2023-12-31 | ₩17.71 Billion | +163.62% |
| 2022-12-31 | ₩-27.83 Billion | +52.24% |
| 2021-12-31 | ₩-58.27 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tomocube Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 251622320000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩6.52 Billion | 15.54% |
| Other Components | ₩100.99 Billion | 240.50% |
| Total Equity | ₩41.99 Billion | 100.00% |
Tomocube Inc Competitors by Market Cap
The table below lists competitors of Tomocube Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China National Complete Plant Import & Export Corp Ltd
SHE:000151
|
$293.72 Million |
|
PARATUS ENERGY SERVICES LTD
OL:PLSV
|
$293.87 Million |
|
The India Cements Limited
NSE:INDIACEM
|
$293.88 Million |
|
Hoasen Group
VN:HSG
|
$293.90 Million |
|
Royal Group Co Ltd
SHE:002329
|
$293.71 Million |
|
Anhui Sunhere Pharmaceutical Excipients Co Ltd
SHE:300452
|
$293.70 Million |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
$293.70 Million |
|
One United Properties SA
RO:ONE
|
$293.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tomocube Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 17,707,733,110 to 41,990,145,480, a change of 24,282,412,370 (137.1%).
- Net loss of 8,302,382,990 reduced equity.
- Share repurchases of 33,335,310,000 reduced equity.
- New share issuances of 33,335,310,000 increased equity.
- Other factors increased equity by 32,584,795,360.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-8.30 Billion | -19.77% |
| Share Repurchases | ₩33.34 Billion | -79.39% |
| Share Issuances | ₩33.34 Billion | +79.39% |
| Other Changes | ₩32.58 Billion | +77.6% |
| Total Change | ₩- | 137.13% |
Book Value vs Market Value Analysis
This analysis compares Tomocube Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 16.56x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | ₩-5460.95 | ₩53300.00 | x |
| 2022-12-31 | ₩-2186.29 | ₩53300.00 | x |
| 2023-12-31 | ₩1390.89 | ₩53300.00 | x |
| 2024-12-31 | ₩3218.23 | ₩53300.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tomocube Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -139.80%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 1.04x
- Recent ROE (-19.77%) is above the historical average (-38.19%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | -1190.54% | 0.05x | 0.00x | ₩-13.52 Billion |
| 2022 | 0.00% | 1567.93% | 0.07x | 0.00x | ₩32.12 Billion |
| 2023 | -132.99% | -628.46% | 0.19x | 1.12x | ₩-25.32 Billion |
| 2024 | -19.77% | -139.80% | 0.14x | 1.04x | ₩-12.50 Billion |
Industry Comparison
This section compares Tomocube Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tomocube Inc (475960) | ₩37.60 Billion | 0.00% | 0.09x | $293.71 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |